EP3512518
Forðaverkun búprenórfínsamsetningar
Status:
EP einkaleyfi í gildi á ÍslandiEP appl. date:
12.9.2017EP published:
26.10.2022EP application number:
17850245.6
EP translation filed:
9.1.2023Grant published:
15.2.2023EPO information:
European Patent Register
Max expiry date:
11.9.2037Expiry date:
11.9.2026Next due date:
30.9.2026
Title in English:
SUSTAINED-RELEASE BUPRENORPHINE FORMULATIONSLanguage of the patent:
English
Timeline
Today
12.9.2017EP application
26.10.2022EP Publication
9.1.2023Translation submitted
15.2.2023Registration published
11.9.2026Expires
Owner
Name:
Alar Pharmaceuticals Inc.Address:
Rm. 312, 3F., No. 19, Keyuan Rd Xitun Dist, Taichung City, 40763, TW
Inventor
Name:
LIN, Tong-HoAddress:
Taipei City 106, TW
Name:
WEN, Yung-ShunAddress:
Taipei City 106, TW
Name:
LIANG, Jui-WeiAddress:
Taipei City 106, TW
Agent
Name:
Árnason Faktor ehf.Address:
Guðríðarstíg 2-4, 113, Reykjavík,
Priority
Number:
201662394168 PDate:
13.9.2016Country:
US
Classification
Categories:
A61K 31/485, A61K 9/08, A61K 47/10, A61K 47/22, A61P 25/36, A61P 25/04, A61P 25/24, A61K 47/14, A61K 47/20, A61K 9/00
Annual fees
Number
Paid
Expires
Payer
Number: 7
Paid: 22.9.2023
Expires: 11.9.2024
Payer: CPA Global (Patrafee) AB
Number: 8
Paid: 22.8.2024
Expires: 11.9.2025
Payer: Árnason Faktor ehf.
Number: 9
Paid: 10.9.2025
Expires: 11.9.2026
Payer: Árnason Faktor ehf.